Novartis AG tried to squash any thoughts that it had a nefarious intent in not disclosing the data fraud it knew about before approval of its gene therapy Zolgensma, saying the company wanted a full understanding of the issue first before bringing it to the attention of regulators.
CEO Vasant Narasimhan said during a 7 August conference call with analysts that the company determined safety, efficacy, and quality were not in danger due to the manipulation and as such decided to wait until its investigation was